Literature DB >> 23563262

COPD prognosis in relation to diagnostic criteria for airflow obstruction in smokers.

Reinier P Akkermans1, Marion Biermans, Bas Robberts, Gerben ter Riet, Annelies Jacobs, Chris van Weel, Michel Wensing, Tjard Schermer.   

Abstract

The aim of this study was to establish which cut-off point for the forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio (i.e. fixed 0.70 or lower limit of normal (LLN) cut-off point) best predicts accelerated lung function decline and exacerbations in middle-aged smokers. We performed secondary analyses on the Lung Health Study dataset. 4045 smokers aged 35-60 years with mild-to-moderate obstructive pulmonary disease were subdivided into categories based on presence or absence of obstruction according to both FEV1/FVC cut-off points. Post-bronchodilator FEV1 decline served as the primary outcome to compare subjects between the categories. 583 (14.4%) subjects were nonobstructed and 3230 (79.8%) subjects were obstructed according to both FEV1/FVC cut-off points. 173 (4.3%) subjects were obstructed according to the fixed cut-off point, but not according to the LLN cut-off point ("discordant" subjects). Mean±SE post-bronchodilator FEV1 decline was 41.8±2.0 mL·year(-1) in nonobstructed subjects, 43.8±3.8 mL·year(-1) in discordant subjects and 53.5±0.9 mL·year(-1) in obstructed subjects (p<0.001). Our study showed that FEV1 decline in subjects deemed obstructed according to a fixed criterion (FEV1/FVC <0.70), but non-obstructed by a sex- and age-specific criterion (LLN) closely resembles FEV1 decline in subjects designated as non-obstructed by both criteria. Sex and age should be taken into account when assessing airflow obstruction in middle-aged smokers.

Entities:  

Mesh:

Year:  2013        PMID: 23563262     DOI: 10.1183/09031936.00158212

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease.

Authors:  Gabrielle Y Liu; Ravi Kalhan
Journal:  Chest       Date:  2021-04-15       Impact factor: 10.262

2.  Diagnostic accuracy of pre-bronchodilator FEV1/FEV6 from microspirometry to detect airflow obstruction in primary care: a randomised cross-sectional study.

Authors:  Lisette van den Bemt; Bram C W Wouters; Joke Grootens; Joke Denis; Patrick J Poels; Tjard R Schermer
Journal:  NPJ Prim Care Respir Med       Date:  2014-08-14       Impact factor: 2.871

3.  Predictors of accelerated FEV1 decline in adults with airflow limitation-Findings from the Health2006 cohort.

Authors:  Camilla Boslev Baarnes; Betina H Thuesen; Allan Linneberg; Amalie S Ustrup; Signe Knag Pedersen; Charlotte Suppli Ulrik
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

4.  Is the GOLD guideline for diagnosing obstruction in COPD discriminatory in predicting severe future COPD-related exacerbations and death?

Authors:  Melissa J McDonnell; Michael Harrison; Robert M Rutherford
Journal:  Breathe (Sheff)       Date:  2021-12

5.  Machine Learning Methods for the Diagnosis of Chronic Obstructive Pulmonary Disease in Healthy Subjects: Retrospective Observational Cohort Study.

Authors:  Shigeo Muro; Masato Ishida; Yoshiharu Horie; Wataru Takeuchi; Shunki Nakagawa; Hideyuki Ban; Tohru Nakagawa; Tetsuhisa Kitamura
Journal:  JMIR Med Inform       Date:  2021-07-06

6.  Should the diagnosis of COPD be based on a single spirometry test?

Authors:  Tjard R Schermer; Bas Robberts; Alan J Crockett; Bart P Thoonen; Annelies Lucas; Joke Grootens; Ivo J Smeele; Cindy Thamrin; Helen K Reddel
Journal:  NPJ Prim Care Respir Med       Date:  2016-09-29       Impact factor: 2.871

7.  Assessment of comorbidities and prognosis in patients with COPD diagnosed with the fixed ratio and the lower limit of normal: a systematic review and meta-analysis.

Authors:  Huaiyu Xiong; Qiangru Huang; Tiankui Shuai; Lei Zhu; Chuchu Zhang; Meng Zhang; Yalei Wang; Jian Liu
Journal:  Respir Res       Date:  2020-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.